495 reports of this reaction
1.8% of all GENTAMICIN SULFATE reports
#7 most reported adverse reaction
SEPSIS is the #7 most commonly reported adverse reaction for GENTAMICIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 495 FDA adverse event reports linking GENTAMICIN SULFATE to SEPSIS. This represents approximately 1.8% of all 27,380 adverse event reports for this drug.
Patients taking GENTAMICIN SULFATE who experience sepsis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPSIS is a less commonly reported adverse event for GENTAMICIN SULFATE, but still significant enough to appear in the safety profile.
In addition to sepsis, the following adverse reactions have been reported for GENTAMICIN SULFATE:
The following drugs have also been linked to sepsis in FDA adverse event reports:
SEPSIS has been reported as an adverse event in 495 FDA reports for GENTAMICIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPSIS accounts for approximately 1.8% of all adverse event reports for GENTAMICIN SULFATE, making it a notable side effect.
If you experience sepsis while taking GENTAMICIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.